French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge
Clémence Lacroix(Inserm), Joëlle Micallef(Institut de Neurosciences des Systèmes), Francesco Salvo(Université de Bordeaux), M. Benkebil(Agence Nationale de Sécurité du Médicament et des Produits de Santé), Nathalie Massy(Centre Hospitalier Universitaire de Rouen), Valérie Gras‐Champel(Centre Hospitalier Universitaire Amiens-Picardie), A.‐P. Jonville‐Béra(Université de Tours), Aurélie Grandvuillemin(Université de Bourgogne), Céline Mounier(Agence Nationale de Sécurité du Médicament et des Produits de Santé), Alexandre Pariente(Inserm), Marie‐Blanche Valnet‐Rabier(Centre Hospitalier Universitaire de Besançon), Sophie Gautier(Centre Hospitalier Universitaire de Lille)
Cited by 28
Related Papers
Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study
|BMJ|2016|284
Drug‐induced peripheral oedema: An aetiology‐based review
|British Journal of Clinical Pharmacology|2021|82
French consensus regarding precautions during tracheostomy and post-tracheostomy care in the context of COVID-19 pandemic
|European Annals of Otorhinolaryngology Head and Neck Diseases|2020|76
Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance Database
|Journal of the Neurological Sciences|2019|60